MUC1‑C Targeting with XYA02‑8‑ADC, for Castration‑Resistant and Neuroendocrine Prostate Cancer

In advanced prostate cancer, castration‑resistant and neuroendocrine variants present some of the toughest clinical challenges because they often lose dependence on androgen receptor signaling and become refractory to hormone‑targeted therapies. Within this resistant landscape, MUC1‑C, the C‑terminal subunit of the mucin‑1 oncoprotein, emerges as a promising alternative target. MUC1‑C is aberrantly overexpressed and under‑glycosylated in many aggressive cancers, including castration‑resistant and neuroendocrine prostate cancer, where it promotes lineage plasticity, stem‑cell‑like features, and survival pathways that persist even after long‑term androgen deprivation.

Building on this biology, researchers have developed a novel MUC1‑C–targeted antibody–drug conjugate called XYA02‑8‑ADC, which uses the monoclonal antibody 7B8 directed against an epitope on the MUC1‑C extracellular domain. In prostate cancer cell lines modeling CRPC and NEPC, 7B8 binds to about 90% of cells compared with an isotype‑control antibody, indicating broad surface MUC1‑C expression.
Once bound, the conjugate is rapidly internalized, with efficient uptake observed within approximately three hours at 37 °C, a key requirement for effective payload delivery into the tumor cell. Inside the cell, the ADC releases its cytotoxic payload, typically a microtubule‑targeting agent such as monomethyl auristatin E or a related toxin, via a cleavable linker system similar to those used in other approved ADCs. In these models, XYA02‑8‑ADC achieves potent tumor‑cell killing at low, sub‑nanomolar concentrations, demonstrating strong in‑vitro cytotoxicity across multiple CRPC/NEPC‑relevant lines.

In animal models of prostate cancer, XYA02‑8‑ADC shows substantial antitumor activity. Both intact and castrated nude mice bearing established prostate cancer xenografts were treated with 7.5 mg/kg intravenous doses once weekly for three administrations, after which tumor growth was monitored for more than two months. Under these conditions, the ADC produces approximately 70% tumor growth inhibition, with durable suppression of tumor progression and no significant weight loss or overt organ toxicity. Critically, the antitumor effect is maintained in both androgen‑replete and androgen‑depleted hosts, indicating that MUC1‑C targeting can operate effectively downstream of androgen‑receptor signaling. This independence from continuous androgen deprivation is particularly relevant for patients who have already undergone extensive hormone suppression or have failed newer AR‑pathway inhibitors, because it suggests that meaningful tumor control might be achievable without relying solely on systemic hormone‑targeting strategies.

If clinical development confirms the preclinical findings, XYA02‑8‑ADC could become one of the first tools that specifically addresses the biology of castration‑resistant and neuroendocrine prostate cancer at both the membrane and intracellular levels, offering a new option for a population that has historically had few effective therapies beyond chemotherapy and immunotherapy.

Source.